4317 |
Driving Optimal CV Outcomes: Time Matters |
Young Won Yoon |
Apr. 25. 17 |
4316 |
Bioabsorbable Polymer DES in High Risk Patients |
Chang-Hwan Yoon |
Apr. 25. 17 |
4315 |
[Invited Case Presentation & Focus Review] BVS Scaffold Thrombosis: The Role of OCT |
Evelyn Regar |
Apr. 25. 17 |
4314 |
Magnesium Based Bioresorbable Scaffold Case Presentation |
Vincent On-Hing Kwok |
Apr. 25. 17 |
4313 |
Recent Clinical Evidence of Magnesium Based Bioresorbable Scaffold |
Michael Haude |
Apr. 25. 17 |
4312 |
Magnesium Based Bioresorbable Scaffold- Addressing BRS Safety Concerns |
Georg Daniel Adreas Nollert |
Apr. 25. 17 |
4311 |
Selecting the Appropriate Patients for Long-term DAPT; Insights from PEGASUS TIMI-54 |
David Joel Cohen |
Apr. 25. 17 |
4310 |
Insights on the Initiation and Treatment Duration of Ticagrelor in Acute Coronary Syndromes |
Jang-Whan Bae |
Apr. 25. 17 |
4309 |
Impact of Technique on Early and Late Outcomes Following Coronary Bioresorbable Scaffold Implantation; Analysis from the ABSORB Trials |
Krishna Sudhir |
Apr. 25. 17 |
4308 |
Future Perspective of Bioresorbable Vascular Scaffolds (ABSORBII, ABSORBIII, AIDA-AMC Registry) : Is It a Crisis or a Chance to Move Forward? |
Seung-Jung Park |
Apr. 25. 17 |